行情

PIRS

PIRS

Pieris Pharms
NASDAQ

实时行情|Nasdaq Last Sale

2.090
-0.030
-1.42%
已收盘, 16:00 04/03 EDT
开盘
2.120
昨收
2.120
最高
2.200
最低
2.020
成交量
32.98万
成交额
--
52周最高
6.04
52周最低
1.600
市值
1.15亿
市盈率(TTM)
-3.7142
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测PIRS价格均价为8.00,最高价位10.00,最低价为5.00。

EPS

PIRS 新闻

更多
  • 跟谁学:审计意见措辞与友商不同 因享受萨班斯法案豁免
  • 新浪财经 · 2小时前
  • 油价收复失地 投资者权衡价格战停战的可能性
  • 新浪财经 · 2小时前
  • 驻日美军基地宣布进入公共卫生紧急状态
  • 新浪财经 · 3小时前
  • 石油谈判代表为减产协议奔走 美国的态度成关键
  • 新浪财经 · 3小时前

所属板块

生物技术和医学研究
-0.50%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

PIRS 简况

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.
展开

微牛提供Pieris Pharmaceuticals Inc(NASDAQ-PIRS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PIRS股票新闻,以帮助您做出投资决策。